These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33329311)

  • 1. Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement.
    Paoletti M; Pichiecchio A; Colafati GS; Conte G; Deodato F; Gasperini S; Menni F; Furlan F; Rubert L; Triulzi FM; Cinnante C
    Front Neurol; 2020; 11():569153. PubMed ID: 33329311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease.
    Hsu YK; Chien YH; Shinn-Forng Peng S; Hwu WL; Lee WT; Lee NC; Po-Yu Huang E; Weng WC
    Genet Med; 2023 Jan; 25(1):27-36. PubMed ID: 36399131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome and unmet needs in infantile-onset Pompe disease.
    Hahn A; Schänzer A
    Ann Transl Med; 2019 Jul; 7(13):283. PubMed ID: 31392195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
    Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
    Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.
    Hsueh CY; Huang CY; Yang CF; Chang CC; Lin WS; Cheng HL; Wu SL; Cheng YF; Niu DM
    Orphanet J Rare Dis; 2021 Aug; 16(1):348. PubMed ID: 34353347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.
    Gupta N; Kazi ZB; Nampoothiri S; Jagdeesh S; Kabra M; Puri RD; Muranjan M; Kalaivani M; Rehder C; Bali D; Verma IC; Kishnani PS
    J Pediatr; 2020 Jan; 216():44-50.e5. PubMed ID: 31606152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease.
    Kenney-Jung D; Korlimarla A; Spiridigliozzi GA; Wiggins W; Malinzak M; Nichting G; Jung SH; Sun A; Wang RY; Al Shamsi A; Phornphutkul C; Owens J; Provenzale JM; Kishnani PS
    Mol Genet Metab; 2024 Feb; 141(2):108119. PubMed ID: 38184429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
    Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
    Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical infantile-onset Pompe disease with good prognosis from mainland China: A case report.
    Zhang Y; Zhang C; Shu JB; Zhang F
    World J Clin Cases; 2022 Apr; 10(10):3278-3283. PubMed ID: 35603335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Airway abnormalities in very early treated infantile-onset Pompe disease: A large-scale survey by flexible bronchoscopy.
    Yang CF; Niu DM; Tai SK; Wang TH; Su HT; Huang LY; Soong WJ
    Am J Med Genet A; 2020 Apr; 182(4):721-729. PubMed ID: 31953985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor outcomes in patients with infantile and juvenile Pompe disease: Lessons from neurophysiological findings.
    Brassier A; Pichard S; Schiff M; Bouchereau J; Bérat CM; Caillaud C; Pion A; Khraiche D; Fauroux B; Oualha M; Barnerias C; Desguerre I; Hully M; Maquet M; Deladrière E; de Lonlay P; Gitiaux C
    Mol Genet Metab; 2023 Aug; 139(4):107650. PubMed ID: 37454519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients.
    Al-Hassnan ZN; Khalifa OA; Bubshait DK; Tulbah S; Alkorashy M; Alzaidan H; Alowain M; Rahbeeni Z; Al-Sayed M
    Mol Genet Metab Rep; 2018 Jun; 15():50-54. PubMed ID: 30023291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Timely Needs for Infantile Onset Pompe Disease Newborn Screening-Practice in Taiwan.
    Chiang SC; Chien YH; Chang KL; Lee NC; Hwu WL
    Int J Neonatal Screen; 2020 Jun; 6(2):30. PubMed ID: 33073026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme.
    Yang CF; Liao TE; Chu YL; Chen LZ; Huang LY; Yang TF; Ho HC; Kao SM; Niu DM
    J Med Genet; 2023 May; 60(5):430-439. PubMed ID: 36137614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?
    Broomfield A; Fletcher J; Hensman P; Wright R; Prunty H; Pavaine J; Jones SA
    JIMD Rep; 2018; 39():55-62. PubMed ID: 28726123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
    Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
    Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center.
    Kim MS; Song A; Im M; Huh J; Kang IS; Song J; Yang A; Kim J; Kwon EK; Choi EJ; Han SJ; Park HD; Cho SY; Jin DK
    Korean J Pediatr; 2019 Jun; 62(6):224-234. PubMed ID: 30360039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.
    Byrne BJ; Fuller DD; Smith BK; Clement N; Coleman K; Cleaver B; Vaught L; Falk DJ; McCall A; Corti M
    Ann Transl Med; 2019 Jul; 7(13):290. PubMed ID: 31392202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.